Medivation Inc (MDVN.OQ)

MDVN.OQ on NASDAQ Stock Exchange Global Select Market

108.82USD
30 Jan 2015
Change (% chg)

$0.88 (+0.82%)
Prev Close
$107.94
Open
$107.25
Day's High
$109.62
Day's Low
$106.67
Volume
369,143
Avg. Vol
395,621
52-wk High
$116.86
52-wk Low
$54.38

MDVN.OQ

Chart for MDVN.OQ

About

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company selects technologies for development that can enter human studies within 12-18 months. It develops technologies without regard to... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $8,447.12
Shares Outstanding(Mil.): 77.62
Dividend: --
Yield (%): --

Financials

  MDVN.OQ Industry Sector
P/E (TTM): 77.02 188.86 38.54
EPS (TTM): 1.41 -- --
ROI: 29.45 -1.23 18.06
ROE: 74.30 -3.07 18.83
Search Stocks

CORRECTED-UPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints

(Corrects paragraph 6 to say Xtandi is marketed by Medivation and Astellas)

10 Nov 2014

U.S. FDA approves expanded use of Medivation prostate cancer drug

- U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

10 Sep 2014

UPDATE 1-U.S. FDA approves expanded use of Medivation prostate cancer drug

Sept 10 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

10 Sep 2014

U.S. FDA okays expanded use of Medivation prostate cancer drug

Sept 10 - U.S. health regulators approved the use of Medivation Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the company said on Wednesday, significantly expanding the potential patient population for the oral medicine.

10 Sep 2014

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $100.14 -2.24
Sanofi SA (SASY.PA) €82.00 -0.26
Bayer AG (BAYGn.DE) €128.05 -0.70
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks